The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis.

Background: Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion.

Methods: The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission.